ARS Pharmaceuticals (SPRY) Operating Expenses (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Operating Expenses of $82.8 million for Q1 2026, up 19.09% sequentially from $69.6 million in Q4 2025, and up 83.45% YoY from $45.2 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Operating Expenses (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Operating Expenses for 7 years, with the latest figure at $82.8 million in Q1 2026.
- Quarterly Operating Expenses rose 83.45% year-over-year to $82.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301.4 million (up 142.69% YoY) and the FY2025 annual result came in at $263.7 million, up 185.94% from the prior year.
- Operating Expenses grew to $82.8 million in Q1 2026 per SPRY's latest filing, from $69.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $85.7 million in Q3 2025 and troughed at $6.8 million in Q2 2022.
- A 5-year average of $32.0 million and a median of $18.7 million in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses tumbled 72.22% in 2022, then jumped 299.82% in 2025.
- Over 5 years, Operating Expenses stood at $15.4 million in 2022, then slumped by 33.78% to $10.2 million in 2023, then jumped by 285.14% to $39.4 million in 2024, then soared by 76.6% to $69.6 million in 2025, then rose by 19.09% to $82.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $82.8 million, $69.6 million, and $85.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 95.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.12 Mn |
| Mar 31, 2026 | 82.83 Mn |
| Dec 31, 2025 | 69.55 Mn |
| Sep 30, 2025 | 85.69 Mn |
| Jun 30, 2025 | 63.33 Mn |
| Mar 31, 2025 | 45.15 Mn |
| Dec 31, 2024 | 39.38 Mn |
| Sep 30, 2024 | 23.82 Mn |
| Jun 30, 2024 | 15.84 Mn |
| Mar 31, 2024 | 13.19 Mn |
| Dec 31, 2023 | 10.23 Mn |
| Sep 30, 2023 | 17.98 Mn |
| Jun 30, 2023 | 20.61 Mn |
| Mar 31, 2023 | 18.73 Mn |
| Dec 31, 2022 | 15.44 Mn |
| Sep 30, 2022 | 6.82 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 7.76 Mn |
| Dec 31, 2021 | -41.12 Mn |
| Sep 30, 2021 | 22.68 Mn |